CENTRE FOR DATA ENRICHED MEDICINE (TEAMPERMED)

Projektinformationen

TeamPerMed

ID Finanzhilfevereinbarung: 101060011

DOI

10.3030/101060011

EK-Unterschriftsdatum 28 April 2023

Startdatum 1 September 2023

Enddatum 31 August 2029

Finanziert unter

• Widening participation and spreading excellence

Gesamtkosten

€ 15 000 000,00

EU-Beitrag

€ 15 000 000,00

Koordiniert durch

TARTU ULIKOOL
Estonia

Periodic Reporting for period 1 - TeamPerMed (CENTRE FOR DATA ENRICHED MEDICINE (TEAMPERMED))

Berichtszeitraum: 2023-09-01 bis 2025-02-28

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Through this project, the University of Tartu along with Tartu University Hospital will form the independent Centre for Personalised Medicine (TeamPerMed) which will be a multi-disciplinary centre that integrates expertise in Genomics, IT, Clinical Medicine and Socio-Economic Analysis to create a scalable framework for developing clinical guidelines and clinical decision support (CDS) tools that can be effectively integrated into healthcare systems.
With the guidance from our expert partners, Erasmus Medical Centre and the University of Helsinki, TeamPerMed will seek to become a recognized regional/European leader in using electronic health and genomics data to make discoveries regarding the causes and development of disease.
TeamPerMed will contribute to digital transformation in healthcare by developing tools and protocols that will allow to make better use of health care data in research and treatment. Indirectly, we will contribute to green transformation, as our research results will enable healthcare systems to operate more efficiently. The technology, tools and knowledge developed by TeamPerMed will contribute to Europe’s competitiveness in the emerging personalised medicine sector, improving the quality of healthcare and lives of European citizens and paving the way for the ‘next generation’ of medicine.
TeamPerMed’s achievements will make it a role model for institutional and systemic reforms in widening countries, contributing to the improved R&I culture and closure of gaps in R&I performance among EU member states.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

Participant recruitment to the clinical study called "Pragmatic trial assessing polygenic risk driven statin therapy for cardiovascular disease prevention" began in March 2025. This research investigates the potential advantages of intensive preventive statin treatment for healthy men aged 45-80 and women aged 55-80 who possess a high genetic predisposition to coronary artery disease (CAD).

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

.